vs

Side-by-side financial comparison of CASS INFORMATION SYSTEMS INC (CASS) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

CASS INFORMATION SYSTEMS INC is the larger business by last-quarter revenue ($26.2M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). CASS INFORMATION SYSTEMS INC runs the higher net margin — 31.3% vs -177.4%, a 208.7% gap on every dollar of revenue. On growth, CASS INFORMATION SYSTEMS INC posted the faster year-over-year revenue change (-1.3% vs -11.5%). CASS INFORMATION SYSTEMS INC produced more free cash flow last quarter ($4.1M vs $-23.1M). Over the past eight quarters, CASS INFORMATION SYSTEMS INC's revenue compounded faster (-2.8% CAGR vs -12.2%).

Cass Information Systems Inc is a leading provider of integrated financial automation and information management solutions for enterprises. Its core services cover freight payment processing, utility expense management, commercial payment services, and supporting data analytics tools, helping clients streamline financial workflows, cut operational costs, and gain clearer cross-category spending visibility to support smarter business decisions.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CASS vs LAB — Head-to-Head

Bigger by revenue
CASS
CASS
1.3× larger
CASS
$26.2M
$19.6M
LAB
Growing faster (revenue YoY)
CASS
CASS
+10.2% gap
CASS
-1.3%
-11.5%
LAB
Higher net margin
CASS
CASS
208.7% more per $
CASS
31.3%
-177.4%
LAB
More free cash flow
CASS
CASS
$27.2M more FCF
CASS
$4.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CASS
CASS
Annualised
CASS
-2.8%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CASS
CASS
LAB
LAB
Revenue
$26.2M
$19.6M
Net Profit
$8.2M
$-34.7M
Gross Margin
48.5%
Operating Margin
38.1%
-168.5%
Net Margin
31.3%
-177.4%
Revenue YoY
-1.3%
-11.5%
Net Profit YoY
78.3%
-28.8%
EPS (diluted)
$0.61
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CASS
CASS
LAB
LAB
Q4 25
$26.2M
Q3 25
$27.4M
$19.6M
Q2 25
$27.6M
$21.8M
Q1 25
$26.8M
$40.8M
Q4 24
$26.5M
Q3 24
$28.1M
$22.1M
Q2 24
$27.6M
$22.5M
Q1 24
$27.7M
$45.5M
Net Profit
CASS
CASS
LAB
LAB
Q4 25
$8.2M
Q3 25
$9.1M
$-34.7M
Q2 25
$8.9M
$-33.5M
Q1 25
$9.0M
$-26.0M
Q4 24
$4.6M
Q3 24
$2.9M
$-26.9M
Q2 24
$4.5M
$-45.7M
Q1 24
$7.2M
$-32.2M
Gross Margin
CASS
CASS
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
CASS
CASS
LAB
LAB
Q4 25
38.1%
Q3 25
42.3%
-168.5%
Q2 25
22.8%
-118.1%
Q1 25
40.6%
-80.8%
Q4 24
19.7%
Q3 24
13.4%
-120.9%
Q2 24
20.2%
-134.5%
Q1 24
32.1%
-132.2%
Net Margin
CASS
CASS
LAB
LAB
Q4 25
31.3%
Q3 25
33.2%
-177.4%
Q2 25
32.1%
-153.7%
Q1 25
33.5%
-63.8%
Q4 24
17.3%
Q3 24
10.5%
-122.0%
Q2 24
16.2%
-203.3%
Q1 24
25.8%
-70.6%
EPS (diluted)
CASS
CASS
LAB
LAB
Q4 25
$0.61
Q3 25
$0.68
$-0.09
Q2 25
$0.66
$-0.09
Q1 25
$0.66
$-0.07
Q4 24
$0.34
Q3 24
$0.21
$-0.07
Q2 24
$0.32
$-0.12
Q1 24
$0.52
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CASS
CASS
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$758.4M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$243.0M
$399.7M
Total Assets
$2.6B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CASS
CASS
LAB
LAB
Q4 25
$758.4M
Q3 25
$486.6M
$129.4M
Q2 25
$431.2M
$158.6M
Q1 25
$428.9M
$150.9M
Q4 24
$680.1M
Q3 24
$432.0M
$210.6M
Q2 24
$441.7M
$269.8M
Q1 24
$368.3M
$287.1M
Total Debt
CASS
CASS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CASS
CASS
LAB
LAB
Q4 25
$243.0M
Q3 25
$243.4M
$399.7M
Q2 25
$240.8M
$424.5M
Q1 25
$234.2M
$454.6M
Q4 24
$229.0M
Q3 24
$237.6M
$489.3M
Q2 24
$229.9M
$510.3M
Q1 24
$229.5M
$577.3M
Total Assets
CASS
CASS
LAB
LAB
Q4 25
$2.6B
Q3 25
$2.5B
$539.6M
Q2 25
$2.3B
$557.0M
Q1 25
$2.3B
$579.6M
Q4 24
$2.4B
Q3 24
$2.3B
$681.5M
Q2 24
$2.3B
$708.7M
Q1 24
$2.3B
$777.7M
Debt / Equity
CASS
CASS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CASS
CASS
LAB
LAB
Operating Cash FlowLast quarter
$4.8M
$-22.2M
Free Cash FlowOCF − Capex
$4.1M
$-23.1M
FCF MarginFCF / Revenue
15.8%
-118.1%
Capex IntensityCapex / Revenue
2.7%
4.5%
Cash ConversionOCF / Net Profit
0.59×
TTM Free Cash FlowTrailing 4 quarters
$31.8M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CASS
CASS
LAB
LAB
Q4 25
$4.8M
Q3 25
$12.3M
$-22.2M
Q2 25
$-1.3M
$-20.7M
Q1 25
$21.6M
$-30.3M
Q4 24
$18.6M
Q3 24
$-198.0K
$-27.9M
Q2 24
$10.7M
$-39.0M
Q1 24
$9.8M
$-62.5M
Free Cash Flow
CASS
CASS
LAB
LAB
Q4 25
$4.1M
Q3 25
$11.3M
$-23.1M
Q2 25
$-2.6M
$-22.6M
Q1 25
$19.0M
$-35.3M
Q4 24
$18.4M
Q3 24
$-2.2M
$-30.1M
Q2 24
$7.9M
$-41.0M
Q1 24
$6.3M
$-63.3M
FCF Margin
CASS
CASS
LAB
LAB
Q4 25
15.8%
Q3 25
41.1%
-118.1%
Q2 25
-9.5%
-103.6%
Q1 25
71.0%
-86.6%
Q4 24
69.5%
Q3 24
-8.0%
-136.4%
Q2 24
28.6%
-182.2%
Q1 24
22.9%
-138.9%
Capex Intensity
CASS
CASS
LAB
LAB
Q4 25
2.7%
Q3 25
3.8%
4.5%
Q2 25
4.9%
8.7%
Q1 25
9.6%
12.4%
Q4 24
0.7%
Q3 24
7.2%
10.2%
Q2 24
10.1%
8.6%
Q1 24
12.6%
1.7%
Cash Conversion
CASS
CASS
LAB
LAB
Q4 25
0.59×
Q3 25
1.35×
Q2 25
-0.15×
Q1 25
2.41×
Q4 24
4.06×
Q3 24
-0.07×
Q2 24
2.38×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CASS
CASS

Processing Fees$15.9M61%
Financial Fees$9.9M38%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons